Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05906251 · ClinicalTrials.gov registry record · Phase 1
A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)
A Phase 1 study, sponsored by Sarepta Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05906251 is a Phase 1 study that was terminated before completion, run by Sarepta Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT05906251, a Phase 1 study, was terminated before completion, sponsored by Sarepta Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety of SRP-6004 administered by intravenous (IV) infusion in ambulatory participants with LGMD2B/R2 (DYSF related).
Interventions
- GENETIC SRP-6004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2025-06-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05906251
The ClinicalTrials.gov registry entry for NCT05906251 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SRP-6004 is the first listed.
NCT05906251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05906251 about?
NCT05906251 is a clinical study titled "A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)". The primary purpose of this study is to evaluate the safety of SRP-6004 administered by intravenous (IV) infusion in ambulatory participants with LGMD2B/R2 (DYSF related).
What is the current status of trial NCT05906251?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2023-05-22. Estimated completion is 2025-06-13.
What interventions are being tested in trial NCT05906251?
The interventions under investigation include: SRP-6004 (GENETIC).
Who is sponsoring clinical trial NCT05906251?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.